Suggested Readings
Opening Plenary 1: The Case for MPTs
Saving Lives with Multipurpose Prevention Technologies: Turning Ideas into Solutions for Sexual and Reproductive Health
PATH and CAMI
PATH, Seattle, 2010
Panel Discussion 1: The MPT Roadmap so far
Initiative for Multipurpose Prevention Technologies: Request for Multipurpose Vaccine Concepts
Prepared by the Vaccine TPP Working Group, 8 August 2011
Multi-Purpose Prevention Technologies: Technology Attributes and Focus, and Target Product Profile
Prepared by the Drug-Drug& Drug-Device TPP Working Group, 5 August 2011
Multipurpose Prevention Technologies for Reproductive Health: Advancing the Scientific and Product Development Agenda
Report from and "MPT Think Tank." Washington, DC, USA. 5 May 2011
Environmental Scan of Emerging and Available MPTs
CAMI/IMPT
Fall 2011
An Approach to Formative Research in HPV Vaccine Introduction Planning in Low-Resource Settings
Allison Bingham, Amynah Janmohamed, Rosario Bartolini, Hilary M. Creed-Kanashiro, Anne Ruhweza Katahoire, Irfan Khan, Ivan Lyazi, Lysander Menezes, Dan Murokora, Nghi Nguyen Quy and Vivien Tsu
Sociocultural Issues in the Introduction of Human Papillomavirus Vaccine in Low-Resource Settings
Allison Bingham, PhD; Jennifer Kidwell Drake, MPH; D. Scott LaMontagne, PhD, MPH, FRSPH
Assessment of Relevant Cultural Considerations is Essential for the Success of a Vaccine
Bonita F. Stanton
Behavioral Research on Biomedical Sexual Health Technologies: Opportunities and Directions
By Gregory D. Zimet
NIH researchers show how anti-HIV drug acts to block herpes virus
Opening Plenary 2: Introduction of the first MPT: Lessons learned to Facilitate the Successful Introduction of Tenofovir Gel
Insights and Evidence from product Introduction: Lessons for Microbicides
Martha Brady and Elizabeth McGrory
Panel Discussion 2: Pressing Issues in the Field: Hormonal Contraception and HIV Acquisition
Contraceptive Used in Africa May Double Risk of H.I.V.
Pam Belluck
New York Times, October 3, 2011
Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study
Renee Heffron et al.
The Lancet Infectious Diseases, Published online 4 October 2011
Contraceptive risk of HIV long suspected
Meredith Wadman
Nature, Published online 7 October 11
Sex Steroid Hormones, Hormonal Contraception, and the Immunobiology of Human Immunodeficiency Virus-1 Infection
Zdenek Hel, Elizabeth Stringer, and Jiri Mestecky
Endocrine Reviews, February 2010, 31(1):79–97
Hormonal Contraception and HIV: an unanswered question
Charles S Morrison, Kavita Nanda
The Lancet Infectious Diseases, Comment, Published online 4 October 2011
Issues in the Field: Hormonal Contraception and HIV Acquisition
Charles Morrison et al
Best Practice & Research Clinical Obstetrics and Gynaecology
The Guttmacher Institute and USAID developed responses to the findings presented at the IAS in Rome on hormonal contraceptives and HIV acquisition
- Hormonal Contraceptives and HIV Risk – Emerging Evidence in Context
Guttmacher Institute - USAID response to new findings on hormonal contraception and HIV acquisition in uninfected women and HIV transmission from infected women to male partners
USAID
Briefing Note: Hormonal Contraceptives and HIV
Prepared by WHO
Scientists and the media must give a balanced view
A reported link between hormonal contraception and HIV infection deserved a more critical look
James Shelton, Nature, Nov 2011.
Panel Discussion 4: Regulatory Pathways for MPTs
What Regulatory Guidance Exists for Multipurpose Prevention Technologies (MPTs)? A Review of Key Guidance Documents and Their Applicability to MPTs
Martha Brady and Heeyoung Park
Population Council, 2011
